Research Article ISSN 2641-4333

Neurology - Research & Surgery

A Multimodal Regenerative Platform for Spinal Cord Injury: Regionally Specified Neural Progenitor Grafts Synergized with Mitochondria-Targeted Peptides and Placenta–CNS Nano-Organopeptidic Biologics

Mike KS Chan[1,2,3], Michelle BF Wong[1,2], Krista Casazza[4] and Jonathan RT Lakey[2,4*]

[1]*European Wellness Academy, Klosterstrasse 205ID, 67480, Edenkoben, Germany.*

[2]*European Wellness BioMedical Group, Klosterstrasse 205ID, 67480, Edenkoben, Germany.*

[3]*Lincoln University College, Selangor, Malaysia.*

[4]*University of California, Irvine, Department of Surgery and Biomedical Engineering, Irvine CA, USA.*

***Correspondence:**
Jonathan RT Lakey, PhD, MSM Professor Emeritus Departments of Surgery and Biomedical Engineering University of California Irvine, USA, Tel: 714 851 8856.

Received: 01 Mar 2026; **Accepted:** 28 Mar 2026; **Published:** 10 Apr 2026

Citation: Mike KS Chan, Michelle BF Wong, Krista Casazza, et al. A Multimodal Regenerative Platform for Spinal Cord Injury: Regionally Specified Neural Progenitor Grafts Synergized with Mitochondria-Targeted Peptides and Placenta–CNS Nano-Organopeptidic Biologics. Neurol Res Surg. 2026; 9(2): 1-8.

ABSTRACT

Spinal cord injury (SCI) remains a major cause of lifelong neurological disability, with limited therapeutic options capable of restoring function once axonal pathways, myelin integrity, and segmental spinal circuitry are disrupted.

Cell-based regenerative approaches have therefore attracted substantial attention, particularly transplantation of neural stem cells (NSCs) and neural progenitor cells (NPCs), which can survive within injured spinal cord tissue, differentiate into neuronal and glial lineages, and extend axons capable of forming synaptic connections with host circuits. Despite this promise, clinical translation of neural graft–based strategies has been constrained by the complex biology of secondary injury, including ischemia, excitotoxic signaling, inflammatory amplification, and metabolic dysfunction, as well as by challenges related to graft survival, circuit integration, and incomplete reconnection of long descending tracts. Among the molecular processes shaping these constraints, mitochondrial dysfunction has emerged as a principal component of secondary injury biology. Disruption of mitochondrial bioenergetics contributes to oxidative stress, apoptotic signaling, and axonal degeneration, while also influencing neural progenitor survival, differentiation, and regenerative capacity. In experimental models of SCI, mitochondria-targeted peptides stabilize mitochondrial function, reduce oxidative injury, and improve neurological recovery, highlighting mitochondrial stabilization as a tractable therapeutic axis. In parallel, advances in extracellular vesicle biology have revealed that placenta-derived extracellular vesicles (pEVs) and related placenta–brain signaling pathways represent a scalable source of developmentally patterned immunomodulatory and trophic signals capable of influencing neural repair processes.

These vesicular systems carry regulatory RNA, proteins, and lipid mediators that can modulate inflammation, vascular stability, and progenitor cell behavior, suggesting a potential role in reprogramming the injury microenvironment.

Recent trials of allogeneic mesenchymal stromal cell products have demonstrated sustained improvements in functional outcomes in age-related frailty, illustrating the capacity of cell-based or cell-derived therapeutics to exert systemic regenerative signals in humans. Within this framework, a high-potency therapeutic architecture for SCI may combine developmentally patterned spinal or brain–specified NPCs with mitochondria-targeted peptides and nanoformulated organopeptidic biologics derived from spinal cord, central

nervous system, or placental signaling systems. Such a strategy aims to simultaneously reconstruct disrupted neural circuits, stabilize mitochondrial bioenergetics during secondary injury, and remodel immune and vascular niches that influence regenerative integration. The present review outlines the mechanistic rationale for this integrated platform and discusses translational considerations intended to maximize therapeutic potency while preserving safety and clinical feasibility.

Keywords
Spinal cord injury, Neural progenitor cells, Mitochondrial dysfunction, Extracellular vesicles, Placenta-derived vesicles, Nanoformulation, targeted delivery, Neuroregeneration.

Introduction

Traumatic spinal cord injury (SCI) remains a leading cause of irreversible neurological disability [1]. The irreversibility is due to the damage which is not solely limited to the initial mechanical insult but evolves through a temporally structured secondary injury program that expands tissue loss and establishes a chronic, regeneration-inhibitory microenvironment [1-3]. In the primary injury compression, contusion, and/or laceration disrupts axons, blood vessels, and cellular membranes [4]. In parallel, secondary injury develops over hours to months and includes hemorrhage and edema, ischemia–reperfusion injury, excitotoxicity, ionic dysregulation, oxidative stress, and a coordinated neuroimmune response that amplifies neuronal and oligodendroglial death and destabilizes spared circuitry [3]. The biphasic model of SCI is clinically consequential. Whereas the secondary phase is potentially modifiable, it is also the phase during which progressive barriers to repair (e.g., glial and fibrotic scarring, altered extracellular matrix composition, chronic inflammation, demyelination, and maladaptive plasticity) become entrenched [5]. Within this evolving microenvironment, immune signaling emerges as a principal driver of both tissue damage and attempted repair.

Neuroinflammation is a central determinant of lesion evolution and functional prognosis [6]. However, SCI-related neuroinflammation is not monolithic. Rather, it is a dynamic sequence of signaling cues and cellular infiltration waves with distinct, sometimes opposing, effects on neuroprotection versus neurotoxicity [7,8]. Early cytokine and chemokine programs recruit neutrophils, monocytes/macrophages, and lymphocytes, while resident microglia and astrocytes shape phagocytosis, scar architecture, and synaptic remodeling. Of note, immune signaling is interlocked with vascular pathobiology. During this dynamic acute SCI period, blood–spinal cord barrier breakdown, endothelial dysfunction, and microvascular rarefaction limit oxygen and substrate delivery and intensify oxidative stress and metabolic failure [8]. In parallel, SCI exerts systemic immunometabolic consequences that can persist in chronic phases and contribute to infections, metabolic disorders, and multi-organ morbidity. These integrated factors complicate both trial endpoints and the safety/efficacy interpretation of regenerative interventions [9,10].

Within the secondary injury landscape, mitochondrial dysfunction represents a convergent mechanistic bottleneck linking excitotoxic calcium influx, reactive oxygen species production, bioenergetic collapse, and regulated cell death pathways [2]. Mitochondria play a key role in immune cell polarization, axonal degeneration and regenerative competence, and neural progenitor self-renewal/differentiation decisions [11]. As such, mitochondrial integrity resides as an upstream driver of multiple repair-relevant processes. Because mitochondrial failure is both an early contributor to lesion expansion and a chronic constraint on axon maintenance and growth, it is increasingly viewed as a tractable target for "metabolic stabilization" strategies designed to preserve host tissue and create a permissive niche for regeneration [12].

Cell-based therapies, including neural stem cells (NSCs) and neural progenitor cells (NPCs), oligodendrocyte lineage–biased progenitors, Schwann cells, and mesenchymal stromal/stem cells (MSCs), are among the most intensively studied approaches for SCI. These cell-based therapies can, in principle, provide cellular substrates for remyelination, trophic support, immunomodulation, and circuit reconstruction [13,14]. However, the translational record highlights persistent gaps between preclinical promise and clinical effect sizes, driven in part by biological and methodological heterogeneity. Clinical trials vary widely in injury chronicity, lesion level, delivery route (intrathecal vs intraspinal), dose and cell product characterization, rehabilitation co-interventions, and outcome measures, complicating cross-study inference and masking true biological signals [15]. Mechanistically, transplanted cells confront sharply heterogeneous microenvironments across the lesion core, penumbra, and distal tracts [16]. As such, these cell therapies must survive inflammatory and metabolic stress, integrate into scar-modified extracellular matrices, and establish functional connectivity in circuits that have undergone both degenerative and compensatory remodeling [17]. Even when graft survival is achieved, durable recovery likely requires alignment between graft identity and host connectivity rules, including rostrocaudal (regional) patterning and appropriate neuron–glia lineage outputs to support remyelination and synaptic relay formation [18,19].

Regionally specified neural PSCs: mechanism-of-action model linking regional identity to connectivity and functional recovery

Transplantation of NSCs/NPCs has emerged as a leading strategy for anatomical repair in severe SCI because transplanted neural precursors can survive within the lesion environment, differentiate into neurons and glia, extend axons across injured tissue, and establish synaptic connections with host circuitry [20,21]. Experimental studies demonstrate that such grafts can form lesion-spanning relay circuits, allowing host supraspinal signals to traverse otherwise disconnected segments without requiring complete regeneration of disrupted long tracts [22-24]. This relay-based architecture provides a biologically plausible path to restoring signal transmission across injured spinal networks and is

increasingly recognized as one of the most realistic mechanisms through which cell transplantation can produce functional recovery in severe SCI. However, the capacity of transplanted progenitors to establish these relay networks is not determined solely by cell survival or proliferative capacity [20,25]. Increasing evidence indicates that developmental regional identity is a primary determinant of connectivity competence. During directed differentiation, gradients of developmental morphogens (e.g., WNT, FGF, retinoic acid) establish stable transcriptional programs that include colinear HOX gene expression and domain-specific transcription factors [26,27]. These molecular signatures govern neuronal subtype specification, axon guidance receptor repertoires, synaptic adhesion molecule expression, and intrinsic axonal growth programs.

In effect, regional identity encodes the developmental logic that dictates how neurons interpret guidance cues, select synaptic partners, and integrate into specific circuit architectures [28]. This developmental programming becomes functionally consequential. Spinal-patterned progenitors generate neuronal populations whose molecular recognition systems are compatible with spinal tract architecture and segmental interneuron networks [29]. In preclinical SCI models, grafts composed of spinally specified progenitors extend long-distance axons, produce diverse spinal neuronal phenotypes, and integrate within host circuitry [30]. Importantly, host supraspinal projections (e.g., corticospinal, reticulospinal, and monoaminergic inputs) demonstrate selective innervation of graft-derived neurons, while graft neurons project caudally to form synapses with host neurons distal to the lesion [31]. This bidirectional connectivity establishes multi-synaptic relay pathways that bridge injured segments and enable signal transmission through host–graft–host circuits. The efficiency of this relay formation appears to depend strongly on developmental matching between graft and host tissue.

Grafts specified toward homologous spinal identities support greater corticospinal tract regeneration and integration compared with non-matched neural identities, indicating that molecular congruence between host axons and graft neurons enhances axonal entry, synaptic stabilization, and circuit embedding [32]. These observations support a mechanistic framework in which regional identity functions as the upstream determinant of circuit integration, governing both afferent capture from host projections and efferent targeting toward distal spinal networks. Translating this principle into a therapeutic platform requires moving beyond generic “neural” graft products toward developmentally specified progenitor populations matched to lesion geography and functional objectives.

The injured spinal cord is characterized by mitochondrial dysfunction, oxidative stress, inflammatory signaling cascades, and impaired vascular perfusion, conditions that threaten both host neurons and transplanted cells [3].

Mitochondrial dysfunction is tightly coupled to immune and vascular dysregulation after SCI [11,33,34]. Beyond its role as an early determinant of lesion expansion, mitochondrial dysfunction integrates immune, vascular, and progenitor-cell regulatory pathways, thereby positioning metabolic stability as a prerequisite for effective regenerative interventions [11]. Activated microglia and infiltrating macrophages undergo metabolic reprogramming that shapes inflammatory phenotypes, while endothelial damage compromises spinal cord perfusion and amplifies oxidative stress. These processes reinforce each other and contribute to the chronic inhibitory niche that limits regeneration.

Consequently, metabolic stabilization alone may not fully restore the permissive conditions required for durable circuit integration. This recognition motivates a complementary strategy based on nano-organopeptidic biologics derived from or modeled on placenta and CNS signaling systems, which can deliver immunomodulatory and angiogenic cues capable of reshaping the inflammatory and vascular landscape of the injured cord. By combining developmental precision in graft identity with metabolic stabilization and immune–vascular remodeling, such a platform seeks to align cellular, metabolic, and microenvironmental determinants of repair into a coordinated regenerative framework.

Mitochondria-targeted peptides as a secondary-injury metabolic shield

Following SCI, excessive glutamatergic signaling and membrane depolarization produce pathological calcium influx into neurons and glia, leading to mitochondrial calcium overload, disruption of the electron transport chain, and excessive production of reactive oxygen species (ROS) [10]. This cascade promotes lipid peroxidation of mitochondrial membranes, loss of oxidative phosphorylation capacity, and activation of intrinsic apoptotic pathways mediated by mitochondrial outer membrane permeabilization and cytochrome-c release [10]. These events contribute not only to neuronal and oligodendroglial death but also to axonal degeneration and conduction failure within surviving white matter tracts [3]. In experimental models, mitochondrial impairment is therefore strongly associated with lesion expansion, axonal degeneration, and chronic neurological deficits.

Mitochondrial bioenergetics also function as a central regulator of cellular phenotypes that influence regeneration. Mitochondrial metabolism modulates macrophage and microglial polarization states, influences axonal transport and growth cone motility through ATP-dependent cytoskeletal remodeling, and regulates oligodendrocyte survival and myelin maintenance [35,36]. Mitochondrial signaling pathways also influence neural progenitor proliferation and lineage commitment, thereby linking metabolic state to regenerative competence [37]. These converging roles place mitochondria at a critical intersection between acute neuroprotection and longer-term regenerative processes following SCI.

Cardiolipin-targeted tetrapeptides such as SS-31 (elamipretide) represent one of the most extensively studied pharmacologic approaches to restoring mitochondrial integrity after injury. SS-31 selectively accumulates within the inner mitochondrial membrane,

where it binds cardiolipin and stabilizes cardiolipin–cytochrome-c interactions that are essential for efficient electron transport chain function [38]. Through this mechanism, the peptide enhances oxidative phosphorylation efficiency, reduces mitochondrial ROS production, and prevents cardiolipin oxidation without disrupting membrane potential. Recent preclinical work has further clarified the role of SS-31 in traumatic SCI [39-41]. In a rat contusion model, administration of SS-31 significantly reduced oxidative stress, suppressed inflammatory signaling pathways, and improved locomotor recovery, supporting a neuroprotective mechanism mediated through mitochondrial stabilization and attenuation of secondary injury cascades [39]. More recent investigations extend these findings by demonstrating that mitochondrial-targeted peptide therapy can modulate mitochondrial dynamics, including preservation of mitochondrial membrane potential and improved respiratory chain activity within injured spinal tissue [40]. Additional experimental studies indicate that cardiolipin-stabilizing peptides may also influence neuroinflammatory pathways and glial responses, suggesting a broader role for mitochondrial modulation in shaping the injury microenvironment and supporting functional recovery after SCI [42].

Collectively, these observations support a mechanistic framework in which early mitochondrial stabilization limits the propagation of secondary injury while preserving the structural and metabolic substrates required for regeneration.

By reducing apoptosis and necrosis in peri-lesional tissue, mitochondrial protection constrains lesion expansion and preserves residual axonal tracts that can participate in relay formation [43]. At the same time, restoration of mitochondrial ATP production and suppression of oxidative stress create an energetically permissive environment for axonal elongation, synaptic maturation, and oligodendrocyte-mediated remyelination [44]. Within a combinatorial regenerative strategy, mitochondrial peptides therefore function less as direct regenerative agents than as **bioenergetic enablers** that convert anatomical potential into durable circuit integration. In this sense, metabolic stabilization represents a foundational intervention that enhances the probability that transplanted neural progenitors and host neurons can successfully participate in long-range circuit reconstruction following SCI.

Placenta–CNS nano-organopeptidic biologics for immune–vascular remodeling

While metabolic stabilization addresses intracellular vulnerability, durable graft integration requires reshaping the immune and vascular architecture of the injured cord. Placenta-derived extracellular vesicles (pEVs) are lipid-bilayer–encapsulated nanoparticles enriched in regulatory miRNAs, proteins, and bioactive lipids that modulate inflammation, angiogenesis, and tissue remodeling in multiple systems [45,46]. Emerging data describing a placenta–brain signaling axis indicate that placental vesicular cargo can influence neural progenitor proliferation, differentiation, and inflammatory tone, suggesting developmental compatibility with CNS repair biology [47]. In SCI, the therapeutic logic is twofold: immunomodulation and vascular and trophic support.

- Post-injury macrophages and microglia exist along a metabolic and functional spectrum; shifting this balance toward pro-repair phenotypes enhances debris clearance, limits chronic cytokine toxicity, and reduces inhibitory extracellular matrix deposition [8]. pEV-derived or biomimetically engineered nano-organopeptidic fractions enriched for regulatory miRNAs and anti-inflammatory peptides may bias immune metabolism away from glycolytic, proinflammatory states toward oxidative, reparative programs.

- Persistent microvascular dysfunction constrains oxygen delivery and propagates secondary degeneration [2,8]. Placenta-derived vesicles are enriched in pro-angiogenic and endothelial-supportive factors that can enhance neovascularization, stabilize endothelial junctions, and accelerate restoration of perfusion [48]. Improved vascular integrity synergizes with mitochondrial stabilization to sustain ATP-dependent repair processes and reduce chronic inflammatory scarring.

Nano-organopeptidic biologics represent an emerging class of cell-derived or biomimetically engineered therapeutics designed to modulate the injury microenvironment without requiring transplantation of intact cells. In this context, nano-organopeptides refer to nanoformulated, tissue-instructive peptide complexes and/or extracellular vesicle (EV) fractions derived from, or engineered to recapitulate, spinal cord, CNS, or placental signaling milieus. These systems recapitulate the immunomodulatory and angiogenic signaling properties described above which collectively influence inflammatory signaling, angiogenesis, and neuronal survival pathways. Increasing experimental evidence indicates that EV-based therapeutics can reproduce many of the immunomodulatory and trophic effects traditionally attributed to their parent cells, including suppression of pro-inflammatory microglial activation, promotion of angiogenesis, and enhancement of axonal regeneration after SCI [33]. Engineering strategies have further expanded the therapeutic potential of these vesicular systems. Surface functionalization with lesion-targeting ligands can enhance biodistribution to injured spinal tissue, while incorporation of EVs into injectable biomaterials enables spatially controlled and stimulus-responsive cargo release. For example, ROS-responsive hydrogel systems designed to release therapeutic EVs within oxidatively stressed tissue environments have been shown to reinforce angiogenesis, suppress inflammatory signaling, and improve functional recovery in experimental SCI models [49]. These approaches highlight the capacity of nano-scale biologics to deliver coordinated immunometabolic and vascular cues that reshape the inhibitory injury niche.

Importantly, the translational trajectory of EV-based therapeutics has begun to extend into the clinical domain. A recent first-in-human phase I study reported the intrathecal administration of allogeneic human umbilical cord mesenchymal stem cell–

derived exosomes in individuals with complete subacute SCI, demonstrating feasibility and an acceptable safety profile while providing early signals supporting neurological and functional monitoring endpoints [50]. Although preliminary, these findings indicate that cell-derived vesicular therapeutics can be delivered directly to the spinal compartment in humans and monitored using conventional clinical and biomarker frameworks.

Within a regenerative systems framework, nano-organopeptidic biologics therefore function as microenvironmental reprogramming agents. By delivering immunomodulatory and angiogenic signals while influencing extracellular matrix remodeling and astroglial scar architecture, these biologics aim to convert the chronically inhibitory spinal injury niche into one permissive for axonal growth, synaptic stabilization, and graft integration. When integrated with metabolic stabilization strategies and regionally specified neural progenitor grafts, nano-organopeptides provide a mechanistically complementary module that addresses inflammatory and vascular barriers to circuit reconstruction, thereby strengthening the translational potential of multi-component regenerative strategies for SCI. As such, region-coded NPCs provide circuit substrate, mitochondrial peptides preserve and energize the substrate, and nano-organopeptidic biologics remodel the immune–vascular context in which connectivity must mature. The predicted systems-level outcome is multiplicative rather than additive: metabolic stabilization preserves host tracts and enhances graft viability; immune–vascular remodeling reduces inhibitory barriers and restores perfusion; and identity-matched progenitors capitalize on this optimized niche to form stable, functionally relevant relay networks.

Preclinical development framework for a multi-component SCI therapeutic platform

Translational development of combination strategies for SCI increasingly reflects the recognition that injury progression and repair occur across multiple biological domains, including tissue preservation, circuit reconstruction, and microenvironmental remodeling. Experimental models capture complementary aspects of injury biology.

Contusion paradigms reproduce clinically relevant features of traumatic SCI, including graded tissue sparing, cavitation, and progressive gliosis, whereas complete transection or severe lesion models provide stringent tests of axonal relay formation and long-distance growth in conditions where residual host tracts cannot account for recovery [51]. Because SCI evolves through temporally distinct phases, experimental analyses increasingly resolve acute, subacute, and chronic windows of intervention rather than treating treatment timing as a secondary variable [52].

Within this temporal framework, the mitochondrial peptide component primarily intersects with early secondary injury biology, including disruption of mitochondrial respiration, amplification of reactive oxygen species signaling, and activation of inflammatory cell death pathways. Findings, to date, position mitochondrial stabilization as an early determinant of lesion containment and tract preservation, processes that shape the structural substrate available for subsequent regenerative interventions.

The nano-organopeptidic component intersects with intermediate phases of injury evolution characterized by immune activation and vascular remodeling. Following spinal trauma, macrophages, microglia, and endothelial cells undergo dynamic phenotypic transitions that influence tissue repair, angiogenesis, and scar formation. Extracellular vesicle-based biologics and related nano-scale peptide systems have been investigated as modulators of these processes, capable of delivering regulatory RNA and protein cargo that influence inflammatory signaling and vascular stability [53].

Experimental systems incorporating extracellular vesicles within responsive biomaterial matrices have demonstrated improved angiogenesis and functional recovery in SCI models, highlighting the emerging translational potential of controlled-release nano-biologic platforms [49]. In contrast, the neural progenitor graft component operates on a longer biological timescale, reflecting the kinetics of neuronal differentiation, axonal extension, and synaptic maturation. Neural progenitor grafts are assessed not only for survival and lineage allocation but also for the formation of host–graft synaptic interfaces, axonal projection patterns, and electrophysiological relay activity across lesion sites.

Mechanistic resolution is strengthened by integrating histological and molecular analyses across injury domains. For neural grafts, this includes quantification of neuronal and oligodendroglial differentiation, axonal projection patterns, synapse formation, and remyelination. Mitochondrial-directed interventions are evaluated through measures of mitochondrial respiration, oxidative stress markers, lipid peroxidation, and cell-death pathway activation within injured tissue. For nano-organopeptidic biologics, characterization extends to immune cell phenotypes, endothelial integrity, vascular density, and features of astrocytic scar organization that influence axonal permissiveness.

Translational biomarker development increasingly accompanies these experimental analyses. Biomarkers detectable in blood or cerebrospinal fluid offer potential bridges between preclinical findings and clinical monitoring.

Neuroaxonal injury markers such as serum neurofilament light chain have demonstrated prognostic relevance in human SCI [54], while circulating inflammatory, endothelial, and metabolic markers provide additional insight into systemic responses to injury and therapy. In parallel, extracellular vesicle cargo profiling and metabolomic signatures of mitochondrial stress are emerging as potential indicators of biological target engagement.

Because combination platforms integrate multiple biologic modalities, manufacturing and regulatory considerations intersect closely with preclinical development. Neural progenitor products derived from pluripotent stem cells require stringent characterization of genomic stability, residual pluripotency, and developmental identity consistent with rostrocaudal and dorsoventral patterning.

For nano-organopeptidic biologics, quality attributes include particle size distribution, cargo consistency, sterility and endotoxin control, and potency assays linked to defined immunomodulatory or endothelial-support functions. Advances in biomaterial-enabled delivery systems, including stimulus-responsive hydrogels capable of releasing extracellular vesicles in response to oxidative stress, further illustrate the convergence of bioengineering and regenerative medicine approaches in contemporary SCI research. Together, these developments illustrate a shift toward mechanism-resolved translational frameworks in which circuit reconstruction, metabolic stabilization, and microenvironmental remodeling are investigated as interacting components of a unified regenerative strategy. Such frameworks reflect a broader evolution in SCI research, emphasizing integrative experimental design, standardized data structures, and cross-disciplinary therapeutic platforms aimed at restoring neural function after traumatic injury.

Discussion

The translational trajectory for regenerative therapies in SCI must reconcile the biological complexity of the injury with the safety and feasibility requirements of clinical development. A staged implementation of multi-component interventions reflects the underlying pathobiology of SCI rather than merely a pragmatic development strategy. Early interventions targeting metabolic stabilization and immune–vascular modulation address processes that emerge rapidly after injury, including mitochondrial dysfunction, inflammatory amplification, and vascular instability. These mechanisms influence lesion expansion, tissue viability, and the metabolic environment in which regenerative processes subsequently occur. By acting during the earliest phases of secondary injury, such interventions shape the structural and physiological substrate that later determines the success of regenerative therapies. Neural progenitor grafting, by contrast, operates on a longer biological timescale that requires an environment capable of sustaining neuronal survival, axonal extension, and synaptic maturation. Sequential deployment of these therapeutic domains therefore provides a means of testing a central mechanistic premise of regenerative strategies for SCI: that metabolic preservation and microenvironmental remodeling function as enabling conditions for circuit reconstruction rather than ancillary enhancements to cell transplantation.

Within this framework, therapeutic potency cannot be adequately defined by improvements in a single outcome measure. Regenerative efficacy in SCI is more accurately conceptualized as a multidimensional biological profile encompassing structural preservation, cellular integration, microenvironmental transformation, and restoration of functional connectivity. The earliest dimension of this profile involves protection of host tissue, reflected by attenuation of lesion expansion, preservation of white matter tracts, and maintenance of mitochondrial and metabolic stability. A second dimension relates to the performance of transplanted progenitor populations, including their survival, lineage maturation, synapse formation, and electrophysiological competence within host circuitry. Together, these parameters indicate whether grafted cells successfully integrate into the neural architecture of the injured cord.

A third dimension concerns the state of the injury microenvironment. Persistent neuroinflammation, vascular disruption, and extracellular matrix remodeling generate a niche that strongly constrains regeneration. Quantitative assessment of immune cell phenotypes, vascular integrity and perfusion, and astroglial scar architecture therefore provides critical insight into whether therapeutic interventions shift the tissue environment toward conditions permissive for axonal growth and synaptic stabilization. The fourth dimension captures the emergence of functional connectivity within reconstructed circuits. Evidence of relay transmission across lesion sites, combined with task-specific behavioral improvements, links structural integration to restored neural signaling. Durability represents the defining attribute that distinguishes regenerative repair from transient symptomatic improvement. Sustained functional effects following limited dosing, supported by biomarker evidence of biological target engagement, provide the most compelling indication that interventions have altered the underlying disease process. Circulating or cerebrospinal biomarkers reflecting axonal injury, inflammatory activation, and mitochondrial stress offer translational tools for connecting mechanistic engagement with long-term functional outcomes.

Interpretation of these domains is strengthened when evaluated within standardized experimental frameworks that capture the diversity of SCI pathology. Complementary injury models enable differentiation between functional gains arising from tissue preservation and those resulting from newly established circuitry. Incorporation of harmonized data standards and rigorous reporting practices further improves cross-study comparability and supports the translation of preclinical observations into clinical development. In this context, claims of enhanced therapeutic potency derive not from isolated improvements in individual endpoints but from the convergence of structural, cellular, physiological, and functional evidence demonstrating coordinated restoration of neural function after SCI.

References

1. Mensah EO, Chalif JI, Johnston BR, et al. Traumatic spinal cord injury: a review of the current state of art and future directions - what do we know and where are we going? North Am Spine Soc J. 2025; 22: 100601.
2. Slater PG, Domínguez-Romero ME, Villarreal M, et al. Mitochondrial function in spinal cord injury and regeneration. Cell Mol Life Sci CMLS. 2022; 79: 239.
3. Hachem LD, Fehlings MG. Pathophysiology of Spinal Cord Injury. Neurosurg Clin N Am. 2021; 32: 305-313.
4. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front Neurol. 2019; 10: 282.
5. Shafqat A, Albalkhi I, Magableh HM, et al. Tackling the glial scar in spinal cord regeneration: new discoveries and future directions. Front Cell Neurosci. 2023; 17: 1180825.

6. Lee CYP, Chooi WH, Ng SY, et al. Modulating neuroinflammation through molecular, cellular and biomaterial-based approaches to treat spinal cord injury. Bioeng Transl Med. 2023; 8: e10389.
7. Larrea A, Elexpe A, Díez-Martín E, et al. Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers. Curr Issues Mol Biol. 2023; 45: 8552-8585.
8. Hellenbrand DJ, Quinn CM, Piper ZJ, et al. Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation. 2021; 18: 284.
9. Kim HW, Yong H, Shea GKH. Blood-spinal cord barrier disruption in degenerative cervical myelopathy. Fluids Barriers CNS. 2023; 20: 68.
10. DiSabato DJ, Marion CM, Mifflin KA, et al. System failure: Systemic inflammation following spinal cord injury. Eur J Immunol. 2024; 54: e2250274.
11. Su YJ, Wang PW, Weng SW. The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing. Int J Mol Sci. 2021; 22: 2668.
12. Wang B, Huang M, Shang D, et al. Mitochondrial Behavior in Axon Degeneration and Regeneration. Front Aging Neurosci. 2021; 13: 650038.
13. Rahimi Darehbagh R, Seyedoshohadaei SA, Ramezani R, et al. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024; 29: 386.
14. Zipser CM, Cragg JJ, Guest JD, et al. Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials. Lancet Neurol. 2022; 21: 659-670.
15. Dietz VA, Roberts N, Knox K, et al. Fighting for recovery on multiple fronts: The past, present, and future of clinical trials for spinal cord injury. Front Cell Neurosci. 2022; 16: 977679.
16. Huang LY, Sun X, Pan HX, et al. Cell transplantation therapies for spinal cord injury focusing on bone marrow mesenchymal stem cells: Advances and challenges. World J Stem Cells. 2023; 15: 385-399.
17. Kumar A, Kumar N, Pathak Z, et al. Extra Cellular Matrix Remodeling: An Adjunctive Target for Spinal Cord Injury and Intervertebral Disc Degeneration. Neurospine. 2022; 19: 632-645.
18. Dell'Anno MT, Wang X, Onorati M, et al. Human neuroepithelial stem cell regional specificity enables spinal cord repair through a relay circuit. Nat Commun. 2018; 9: 3419.
19. Li C, Luo Y, Li S. The roles of neural stem cells in myelin regeneration and repair therapy after spinal cord injury. Stem Cell Res Ther. 2024; 15: 204.
20. Fischer I, Dulin JN, Lane MA. Transplanting neural progenitor cells to restore connectivity after spinal cord injury. Nat Rev Neurosci. 2020; 21: 366-383.
21. Suzuki H, Imajo Y, Funaba M, et al. Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury. Front Cell Neurosci. 2021; 15: 794692.
22. Bonner JF, Steward O. Repair of spinal cord injury with neuronal relays: From fetal grafts to neural stem cells. Brain Res. 2015; 1619: 115-123.
23. Rosenzweig ES, Brock JH, Lu P, et al. Restorative effects of human neural stem cell grafts on the primate spinal cord. Nat Med. 2018; 24: 484-490.
24. Kumamaru H, Lu P, Rosenzweig ES, et al. Regenerating Corticospinal Axons Innervate Phenotypically Appropriate Neurons within Neural Stem Cell Grafts. Cell Rep. 2019; 26: 2329-2339.e4.
25. Homem CCF, Repic M, Knoblich JA. Proliferation control in neural stem and progenitor cells. Nat Rev Neurosci. 2015; 16: 647-659.
26. Douceau S, Deutsch Guerrero T, Ferent J. Establishing Hedgehog Gradients during Neural Development. Cells. 2023; 12: 225.
27. Schilling TF, Sosnik J, Nie Q. Visualizing retinoic acid morphogen gradients. Methods Cell Biol. 2016; 133: 139-163.
28. Han KA, Yoon TH, Kim J, et al. Specification of neural circuit architecture shaped by context-dependent patterned LAR-RPTP microexons. Nat Commun. 2024; 15: 1624.
29. Ziskind-Conhaim L, Hochman S. Diversity of molecularly defined spinal interneurons engaged in mammalian locomotor pattern generation. J Neurophysiol. 2017; 118: 2956-2974.
30. Tucker A, Baltazar A, Eisdorfer JT, et al. Functional synaptic connectivity of engrafted spinal cord neurons with hindlimb motor circuitry in the injured spinal cord. Nat Commun. 2025; 16: 10423.
31. Ceto S, Sekiguchi KJ, Takashima Y, et al. Neural Stem Cell Grafts Form Extensive Synaptic Networks that Integrate with Host Circuits after Spinal Cord Injury. Cell Stem Cell. 2020; 27: 430-440.e5.
32. Kadoya K, Lu P, Nguyen K, et al. Spinal cord reconstitution with homologous neural grafts enables robust corticospinal regeneration. Nat Med. 2016; 22: 479-487.
33. Zhou B, Yu P, Lin MY, et al. Facilitation of axon regeneration by enhancing mitochondrial transport and rescuing energy deficits. J Cell Biol. 2016; 214: 103-119.
34. Pemberton JM, Pogmore JP, Andrews DW. Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins. Cell Death Differ. 2021; 28: 108-122.
35. Wang Y, Li N, Zhang X, et al. Mitochondrial metabolism regulates macrophage biology. J Biol Chem. 2021; 297: 100904.
36. Wang K, Chen X, Liu M, et al. Mitochondrial dynamics reveal potential to facilitate axonal regeneration after spinal cord injury. J Transl Med. 2025; 23: 617.
37. Garone C, De Giorgio F, Carli S. Mitochondrial metabolism in neural stem cells and implications for neurodevelopmental and neurodegenerative diseases. J Transl Med. 2024; 22: 238.

38. Dong C, Lv D, Dong Y, et al. Advances in Cardiolipin Analysis: Applications in Central Nervous System Disorders and Nutrition Interventions. Biomolecules. 2026; 16: 71.

39. Zhang H, Chen Y, Li F, et al. Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. J Neuroinflammation. 2023; 20: 6.

40. Ravenscraft B, Lee DH, Dai H, et al. Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within in Vitro and in Vivo Models of Spinal Cord Injury. Int J Mol Sci. 2025; 26: 3327.

41. Dong C, Lv D, Dong Y, et al. Advances in Cardiolipin Analysis: Applications in Central Nervous System Disorders and Nutrition Interventions. Biomolecules. 2026; 16: 71.

42. Bradshaw PC, Aldridge JL, Jamerson LE, et al. The Role of Cardiolipin in Brain Bioenergetics, Neuroinflammation, and Neurodegeneration. Mol Neurobiol. 2025; 62: 7022-7040.

43. Pease SE, Segal RA. Preserve and protect: maintaining axons within functional circuits. Trends Neurosci. 2014; 37: 572-582.

44. Spaas J, van Veggel L, Schepers M, et al. Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. Cell Mol Life Sci CMLS. 2021; 78: 4615-4637.

45. Lewis E, Lee SJ, Park HR. Placenta-derived extracellular vesicles in fetal health: emerging insights into brain development and environmental interactions. Exp Mol Med. 2025; 57: 2729-2738.

46. Rosenfeld CS. Placenta Extracellular Vesicles: Messengers Connecting Maternal and Fetal Systems. Biomolecules. 2024; 14: 995.

47. Kinkade JA, Seetharam AS, Sachdev S, et al. Extracellular vesicles from mouse trophoblast cells: Effects on neural progenitor cells and potential participants in the placenta-brain axis. Biol Reprod. 2024; 110: 310-328.

48. Czernek L, Düchler M. Exosomes as Messengers Between Mother and Fetus in Pregnancy. Int J Mol Sci. 2020; 21: 4264.

49. Cao J, Zhang X, Guo J, et al. An engineering-reinforced extracellular vesicle-integrated hydrogel with an ROS-responsive release pattern mitigates spinal cord injury. Sci Adv. 2025; 11: eads3398.

50. Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Stem Cell Res Ther. 2024; 15: 264.

51. Li MQ, Wang QH, Dong CM, et al. Spinal cord injury models: Advantages and disadvantages in the view of pathophysiology and clinical significance. Biochem Biophys Rep. 2025; 42: 102063.

52. Grasso G, Cusimano L, Noto M, et al. Current and emergent therapies targeting spinal cord injury. Brain Spine. 2025; 5: 104243.

53. Primorac D, Brlek P, Bulić L, et al. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls. Int J Mol Sci. 2026; 27: 1509.

54. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015; 86: 273-279.